HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3).

Authors :: Herfarth, K.
Scholz, C. W.
Hübel, K.
Wirths, S.
Buske, C.
Dürig, J.
Forstpointner, R.
Heidegger, S.
Lenz, G.
König, L.
Meißner, J.
Höller, U.
Baues, C.
De‐Colle, C.
Wiegel, T.
Gauler, T.
Li, M.
Combs, S. E.
Eich, H.
Sander, A.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p218-220, 3p
Publication Year :: 2023
Abstract: The prospective, multicentric phase II GAZAI study of the German Lymphoma Alliance (GLA) investigated the efficacy of low dose radiation therapy (2 × 2 Gy) in combination with the anti-CD20 antibody Obinutuzumab in early stage nodal FL. At week 18, metabolic CR (Deauville score (DS) <3) was seen in 46/53 patients (87%; one patient only had a CT without FDG-PET). B Introduction: b The FORT trial demonstrated a higher complete remission (CR) rate using 12 × 2 Gy compared to 2 × 2 Gy in Follicular Lymphoma (FL) (67% vs. 47%). [Extracted from the article]

Full Text Access

Tools